* has a prior history of laboratory-confirmed sars-cov-2 infection (with or without symptoms) within 6 months prior to randomization * has either of the following: human immunodeficiency virus (hiv) with a recent viral load \>50 copies/ml (regardless of cd4 count) or an acquired immunodeficiency syndrome (aids)-defining illness * has a history of hepatitis b virus (hbv) or hepatitis c virus (hcv) infection with any of the following: cirrhosis, end-stage liver disease, hepatocellular carcinoma; aspartate transaminase (ast) and/or (alt) \>3x upper limit of normal at screening * has hypersensitivity or other contraindication to any of the components of the study interventions as determined by the investigator * has any condition for which, in the opinion of the investigator, participation would not be in the best interest of the participant or that could prevent, limit, or confound the protocol-specified assessments including but not limited to participants with conditions that could limit gastrointestinal absorption of capsule contents * has received, is taking, or is anticipated to require any prohibited therapies * has received a covid-19 vaccination with the first dose ≥7 days prior to randomization * is unwilling to abstain from participating in another interventional clinical study through day 29 with an investigational compound or device, including those for covid-19 therapeutics * is living in a household with \>10 people

* has a prior history of laboratory-confirmed sars-cov-2 infection (with or without symptoms) within 6 months prior to randomization * has either of the following: human immunodeficiency virus (hiv) with a recent viral load \>50 copies/ml (regardless of cd4 count) or an acquired immunodeficiency syndrome (aids)-defining illness * has a history of hepatitis b virus (hbv) or hepatitis c virus (hcv) infection with any of the following: cirrhosis, end-stage liver disease, hepatocellular carcinoma; aspartate transaminase (ast) and/or (alt) \>3x upper limit of normal at screening * has hypersensitivity or other contraindication to any of the components of the study interventions as determined by the investigator * has any condition for which, in the opinion of the investigator, participation would not be in the best interest of the participant or that could prevent, limit, or confound the protocol-specified assessments including but not limited to participants with conditions that could limit gastrointestinal absorption of capsule contents * has received, is taking, or is anticipated to require any prohibited therapies * has received a covid-19 vaccination with the first dose ≥7 days prior to randomization * is unwilling to abstain from participating in another interventional clinical study through day 29 with an investigational compound or device, including those for covid-19 therapeutics * is living in a household with \>10 people

has a prior history of laboratory-confirmed sars-cov-2 infection (with or without symptoms) within 6 months prior to randomization has either of the following: human immunodeficiency virus (hiv) with a recent viral load >50 copies/ml (regardless of cd4 count) or an acquired immunodeficiency syndrome (aids)-defining illness has a history of hepatitis b virus (hbv) or hepatitis c virus (hcv) infection with any of the following: cirrhosis, end-stage liver disease, hepatocellular carcinoma; aspartate transaminase (ast) and/or (alt) >3x upper limit of normal at screening has hypersensitivity or other contraindication to any of the components of the study interventions as determined by the investigator has any condition for which, in the opinion of the investigator, participation would not be in the best interest of the participant or that could prevent, limit, or confound the protocol-specified assessments including but not limited to participants with conditions that could limit gastrointestinal absorption of capsule contents has received, is taking, or is anticipated to require any prohibited therapies has received a covid-19 vaccination with the first dose ≥7 days prior to randomization is unwilling to abstain from participating in another interventional clinical study through day 29 with an investigational compound or device, including those for covid-19 therapeutics is living in a household with >10 people

has a prior history of laboratory-confirmed sars-cov-2 infection (with or without symptoms) within 6 months prior to randomization has either of the following: human immunodeficiency virus (hiv) with a recent viral load >50 copies/ml (regardless of cd4 count) or an acquired immunodeficiency syndrome (aids)-defining illness has a history of hepatitis b virus (hbv) or hepatitis c virus (hcv) infection with any of the following: cirrhosis, end-stage liver disease, hepatocellular carcinoma; aspartate transaminase (ast) and/or (alt) >3x upper limit of normal at screening has hypersensitivity or other contraindication to any of the components of the study interventions as determined by the investigator has any condition for which, in the opinion of the investigator, participation would not be in the best interest of the participant or that could prevent, limit, or confound the protocol-specified assessments including but not limited to participants with conditions that could limit gastrointestinal absorption of capsule contents has received, is taking, or is anticipated to require any prohibited therapies has received a covid-19 vaccination with the first dose ≥7 days prior to randomization is unwilling to abstain from participating in another interventional clinical study through day 29 with an investigational compound or device, including those for covid-19 therapeutics is living in a household with >10 people

- has a prior history of laboratory-confirmed sars-cov-2 infection (with or without symptoms) or has a prior positive test results for anti-sars-cov-2 antibodies - is on dialysis or has renal impairment - has either of the following: 1) human immunodeficiency virus (hiv) with a recent viral load >50 copies/ml (regardless of cd4 count) or an acquired immunodeficiency syndrome (aids)-defining illness; or 2) neutrophilic granulocyte absolute count <500/mm^3 - has a history of hepatitis b virus (hbv) or hepatitis c virus (hcv) infection with any of the following: cirrhosis, end-stage liver disease, hepatocellular carcinoma; aspartate transaminase (ast) and/or (alt) >3x upper limit of normal at screening - has a low platelet count or received a platelet transfusion within 5 days prior to randomization - has hypersensitivity or other contraindication to any of the components of the study interventions as determined by the investigator - has any condition for which, in the opinion of the investigator, participation would not be in the best interest of the participant or that could prevent, limit, or confound the protocol-specified assessments including but not limited to participants with conditions that could limit gastrointestinal absorption of capsule contents - has received, is taking, or is anticipated to require any prohibited therapies - has received a covid-19 vaccination with the first dose ≥7 days prior to randomization - is unwilling to abstain from participating in another interventional clinical study through day 29 with an investigational compound or device, including those for covid-19 therapeutics - has more than 1 individual currently (assessed at the time of consent), or within the last month, living in the household with confirmed or suspected covid-19 - is living in a household with >10 people

- has a prior history of laboratory-confirmed sars-cov-2 infection (with or without symptoms) or has a prior positive test results for anti-sars-cov-2 antibodies - is on dialysis or has renal impairment - has either of the following: 1) human immunodeficiency virus (hiv) with a recent viral load >50 copies/ml (regardless of cd4 count) or an acquired immunodeficiency syndrome (aids)-defining illness; or 2) neutrophilic granulocyte absolute count <500/mm^3 - has a history of hepatitis b virus (hbv) or hepatitis c virus (hcv) infection with any of the following: cirrhosis, end-stage liver disease, hepatocellular carcinoma; aspartate transaminase (ast) and/or (alt) >3x upper limit of normal at screening - has a low platelet count or received a platelet transfusion within 5 days prior to randomization - has hypersensitivity or other contraindication to any of the components of the study interventions as determined by the investigator - has any condition for which, in the opinion of the investigator, participation would not be in the best interest of the participant or that could prevent, limit, or confound the protocol-specified assessments including but not limited to participants with conditions that could limit gastrointestinal absorption of capsule contents - has received, is taking, or is anticipated to require any prohibited therapies - has received a covid-19 vaccination with the first dose ≥7 days prior to randomization - is unwilling to abstain from participating in another interventional clinical study through day 29 with an investigational compound or device, including those for covid-19 therapeutics - has more than 1 individual currently (assessed at the time of consent), or within the last month, living in the household with confirmed or suspected covid-19 - is living in a household with >10 people

- has a prior history of laboratory-confirmed sars-cov-2 infection (with or without symptoms) - is on dialysis or has renal impairment - has either of the following: 1) human immunodeficiency virus (hiv) with a recent viral load >50 copies/ml (regardless of cd4 count) or an acquired immunodeficiency syndrome (aids)-defining illness; or 2) neutrophilic granulocyte absolute count <500/mm^3 - has a history of hepatitis b virus (hbv) or hepatitis c virus (hcv) infection with any of the following: cirrhosis, end-stage liver disease, hepatocellular carcinoma; aspartate transaminase (ast) and/or (alt) >3x upper limit of normal at screening - has a low platelet count or received a platelet transfusion within 5 days prior to randomization - has hypersensitivity or other contraindication to any of the components of the study interventions as determined by the investigator - has any condition for which, in the opinion of the investigator, participation would not be in the best interest of the participant or that could prevent, limit, or confound the protocol-specified assessments including but not limited to participants with conditions that could limit gastrointestinal absorption of capsule contents - is taking or is anticipated to require any prohibited therapies - has received a covid-19 vaccination with the first dose ≥7 days prior to randomization - is unwilling to abstain from participating in another interventional clinical study through day 29 with an investigational compound or device, including those for covid-19 therapeutics - has more than 1 individual currently (assessed at the time of consent), or within the last month, living in the household with confirmed or suspected covid-19 - is living in a household with >10 people

- has a prior history of laboratory-confirmed sars-cov-2 infection (with or without symptoms) - is on dialysis or has renal impairment - has either of the following: 1) human immunodeficiency virus (hiv) with a recent viral load >50 copies/ml (regardless of cd4 count) or an acquired immunodeficiency syndrome (aids)-defining illness; or 2) neutrophilic granulocyte absolute count <500/mm^3 - has a history of hepatitis b virus (hbv) or hepatitis c virus (hcv) infection with any of the following: cirrhosis, end-stage liver disease, hepatocellular carcinoma; aspartate transaminase (ast) and/or (alt) >3x upper limit of normal at screening - has a low platelet count or received a platelet transfusion within 5 days prior to randomization - has hypersensitivity or other contraindication to any of the components of the study interventions as determined by the investigator - has any condition for which, in the opinion of the investigator, participation would not be in the best interest of the participant or that could prevent, limit, or confound the protocol-specified assessments including but not limited to participants with conditions that could limit gastrointestinal absorption of capsule contents - is taking or is anticipated to require any prohibited therapies - has received a covid-19 vaccination with the first dose ≥7 days prior to randomization - is unwilling to abstain from participating in another interventional clinical study through day 29 with an investigational compound or device, including those for covid-19 therapeutics - has more than 1 individual currently (assessed at the time of consent), or within the last month, living in the household with confirmed or suspected covid-19 - is living in a household with >10 people